Xtant Medical (NYSEAMERICAN:XTNT) Announces Earnings Results

Xtant Medical (NYSEAMERICAN:XTNT) issued its earnings results on Tuesday. The medical device company reported $0.03 earnings per share for the quarter, reports. The company had revenue of $32.36 million for the quarter, compared to analyst estimates of $30.75 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Here are the key takeaways from Xtant Medical’s conference call:

• Q4 revenue was $32.4 million (+3% YoY) and full?year 2025 revenue was $133.9 million (+14% YoY), with adjusted EBITDA of $16.3 million and $5.0 million net income, reflecting sustained operational discipline and positive cash flow.
• Management completed the sale of Coflex and international Paradigm Spine assets to Companion Spine for about $21.4 million in early December and used proceeds to reduce debt and sharpen focus on core high?margin biologics.
• 2026 guidance of $95M–$99M excludes the divested businesses and one?time license income, implying a material year?over?year revenue decline even as the company expects to preserve positive free cash flow.
• Company has doubled regional sales reps, plans to expand national accounts, and launched new products (nanOss Strata, CollagenX) — management expects these investments and a full biologics portfolio to accelerate organic biologics growth as reps ramp.
• Hardware revenue is expected to decline steadily (approaching high?teens% in 2026) and inventory/obsolescence charges remain a headwind; management forecasts gross margin around the low?60s% for 2026.

Xtant Medical Stock Down 4.6%

XTNT opened at $0.53 on Thursday. The firm has a market cap of $74.49 million, a P/E ratio of 17.74 and a beta of -0.16. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.06 and a current ratio of 2.21. The business has a 50 day moving average price of $0.59 and a 200 day moving average price of $0.67. Xtant Medical has a twelve month low of $0.34 and a twelve month high of $0.95.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Craig Hallum restated a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. BTIG Research lowered their target price on shares of Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $1.00.

Hedge Funds Weigh In On Xtant Medical

A number of institutional investors have recently modified their holdings of XTNT. Nantahala Capital Management LLC boosted its holdings in shares of Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the period. Renaissance Technologies LLC raised its holdings in Xtant Medical by 28.8% in the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after acquiring an additional 205,945 shares during the period. Vanguard Group Inc. raised its holdings in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the period. Wiregrass Investment Management LLC acquired a new position in Xtant Medical during the 4th quarter worth $81,000. Finally, Mink Brook Asset Management LLC lifted its position in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after acquiring an additional 60,997 shares during the last quarter. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.